Definitive Healthcare (NASDAQ:DH) Trading Down 4.9% – What’s Next?

Definitive Healthcare Corp. (NASDAQ:DH)’s share price traded down 4.9% during mid-day trading on Wednesday . The stock traded as low as $4.76 and last traded at $4.77. 104,155 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 756,992 shares. The stock had previously closed at $5.01.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DH. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Barclays reissued an “underweight” rating and issued a $4.00 price target on shares of Definitive Healthcare in a research note on Monday, January 13th. Finally, Stephens assumed coverage on shares of Definitive Healthcare in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Definitive Healthcare currently has a consensus rating of “Hold” and an average price target of $5.72.

Definitive Healthcare Stock Down 0.5 %

The firm has a 50 day moving average price of $4.41 and a 200-day moving average price of $4.45. The firm has a market cap of $565.24 million, a price-to-earnings ratio of -1.59, a price-to-earnings-growth ratio of 3.70 and a beta of 1.41. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Thursday, November 7th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.03). The company had revenue of $62.70 million for the quarter, compared to the consensus estimate of $61.66 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. During the same quarter last year, the business posted $0.01 EPS. As a group, equities analysts predict that Definitive Healthcare Corp. will post 0.15 EPS for the current fiscal year.

Insider Transactions at Definitive Healthcare

In other news, insider William Moschella sold 45,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $4.70, for a total transaction of $211,500.00. Following the completion of the transaction, the insider now directly owns 433,830 shares of the company’s stock, valued at $2,039,001. This trade represents a 9.40 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 14.84% of the stock is owned by insiders.

Institutional Investors Weigh In On Definitive Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in DH. Renaissance Technologies LLC raised its stake in Definitive Healthcare by 50.5% in the second quarter. Renaissance Technologies LLC now owns 28,900 shares of the company’s stock valued at $158,000 after buying an additional 9,700 shares during the period. Hsbc Holdings PLC acquired a new position in shares of Definitive Healthcare during the 2nd quarter worth approximately $127,000. Marshall Wace LLP bought a new stake in Definitive Healthcare in the 2nd quarter valued at $1,535,000. Cubist Systematic Strategies LLC boosted its position in Definitive Healthcare by 213.8% during the second quarter. Cubist Systematic Strategies LLC now owns 219,481 shares of the company’s stock worth $1,198,000 after purchasing an additional 149,533 shares during the period. Finally, AQR Capital Management LLC bought a new position in Definitive Healthcare during the second quarter worth $155,000. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.